MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Начало・Списък с акции・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

339.06 1.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

329.96

Максимум

343.01

Ключови измерители
By Trading Economics
Приходи	-65M 186M
Продажби	-152M 1.1B
P/E Средно за сектора	141.777 66.418
EPS	1.25
Марж на печалбата	16.993
Служители	2,500
EBITDA	-152M 145M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+35.88% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.5B 44B
Предишно отваряне	337.24
Предишно затваряне	339.06

Настроения в новините

By Acuity

50%

154 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

256.565 / 269.81 Подкрепа & съпротива

Alnylam Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.04.2026 г., 23:25 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13.04.2026 г., 22:45 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13.04.2026 г., 18:03 ч. UTC

Печалби

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13.04.2026 г., 23:58 ч. UTC

Печалби

Review & Preview: Earnings Time -- Barrons.com

13.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13.04.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13.04.2026 г., 21:26 ч. UTC

Значими събития в новините

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13.04.2026 г., 21:16 ч. UTC

Печалби

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13.04.2026 г., 19:59 ч. UTC

Пазарно говорене

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13.04.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13.04.2026 г., 19:27 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Precious Metals Market Talk on April 9

13.04.2026 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13.04.2026 г., 18:43 ч. UTC

Пазарно говорене

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Alnylam Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

35.88% нагоре

12-месечна прогноза

Среден 452.47 USD 35.88%

Висок 549 USD

Нисък 330 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Alnylam Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Alnylam Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

256.565 / 269.81Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

154 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.